WO2003023059A3 - Verfahren und kit zur diagnostik oder behandlungskontrolle von darmkrebs - Google Patents

Verfahren und kit zur diagnostik oder behandlungskontrolle von darmkrebs Download PDF

Info

Publication number
WO2003023059A3
WO2003023059A3 PCT/EP2002/009983 EP0209983W WO03023059A3 WO 2003023059 A3 WO2003023059 A3 WO 2003023059A3 EP 0209983 W EP0209983 W EP 0209983W WO 03023059 A3 WO03023059 A3 WO 03023059A3
Authority
WO
WIPO (PCT)
Prior art keywords
diagnosis
kit
treatment control
intestinal
intestinal carcinoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2002/009983
Other languages
English (en)
French (fr)
Other versions
WO2003023059A2 (de
Inventor
Winfried Albert
Pia Steffens
Alf-Andreas Krehan
Monica Stefan
Stefanie Waschuetza
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alere Diagnostics GmbH
Original Assignee
Adnagen GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10143775A external-priority patent/DE10143775A1/de
Priority claimed from PCT/EP2002/005489 external-priority patent/WO2003023057A2/de
Application filed by Adnagen GmbH filed Critical Adnagen GmbH
Priority to DE50209932T priority Critical patent/DE50209932D1/de
Priority to EP02772273A priority patent/EP1409745B1/de
Priority to US10/488,728 priority patent/US20060246430A1/en
Publication of WO2003023059A2 publication Critical patent/WO2003023059A2/de
Publication of WO2003023059A3 publication Critical patent/WO2003023059A3/de
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Die vorliegende Erfindung betrifft ein Diagnose-Kit sowie ein Verfahren zur Diagnostik oder Behandlungskontrolle von Darmkrebs bei einem Menschen. Hierzu wird in einer Blutprobe des Menschen das Vorhandensein oder Fehlen von mindestens zwei verschiedenen mRNS erfaßt, die für verschiedene der Tumormarkerproteine CK20, EGF-R, CEA, GA733.2, PDGF-β und/oder Stanniocalcin kodieren. Daraus wird dann auf das Vorhandensein von Darmtumorzellen in der Blutprobe und damit auf mögliche Metastsierung geschlossen.
PCT/EP2002/009983 2001-09-06 2002-09-06 Verfahren und kit zur diagnostik oder behandlungskontrolle von darmkrebs Ceased WO2003023059A2 (de)

Priority Applications (3)

Application Number Priority Date Filing Date Title
DE50209932T DE50209932D1 (de) 2001-09-06 2002-09-06 Verfahren und kit zur diagnostik oder behandlungskontrolle von darmkrebs
EP02772273A EP1409745B1 (de) 2001-09-06 2002-09-06 Verfahren und kit zur diagnostik oder behandlungskontrolle von darmkrebs
US10/488,728 US20060246430A1 (en) 2001-09-06 2002-09-06 Method and kit for the diagnosis or treatment control of intestinal carcinoma

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE10143775A DE10143775A1 (de) 2001-09-06 2001-09-06 Verfahren und Kit zur Diagnostik oder Behandlungskontrolle von Darmkrebs
DE10143775.7 2001-09-06
PCT/EP2002/005489 WO2003023057A2 (de) 2001-09-06 2002-05-17 Verfahren und diagnose-kit zur selektionierung und/oder zum qualitativen und/oder quantitativen nachweis von zellen
EPPCT/EP02/05489 2002-05-17

Publications (2)

Publication Number Publication Date
WO2003023059A2 WO2003023059A2 (de) 2003-03-20
WO2003023059A3 true WO2003023059A3 (de) 2003-11-13

Family

ID=26010081

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/009983 Ceased WO2003023059A2 (de) 2001-09-06 2002-09-06 Verfahren und kit zur diagnostik oder behandlungskontrolle von darmkrebs

Country Status (4)

Country Link
EP (1) EP1409745B1 (de)
DE (1) DE50209932D1 (de)
ES (1) ES2284927T3 (de)
WO (1) WO2003023059A2 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2466896A1 (en) 2001-09-06 2003-03-20 Adnagen Ag Method and diagnosis kit for selecting and or qualitative and/or quantitative detection of cells
CN1922304A (zh) * 2003-10-31 2007-02-28 维特克公司 用于检测循环肿瘤和内皮细胞的血液测试样机和方法
US20070134670A1 (en) * 2003-12-12 2007-06-14 Bayer Pharmaceuticals Corporation Methods for prediction and prognosis of cancer, and monitoring cancer therapy
US8921102B2 (en) 2005-07-29 2014-12-30 Gpb Scientific, Llc Devices and methods for enrichment and alteration of circulating tumor cells and other particles
EP2029779A4 (de) 2006-06-14 2010-01-20 Living Microsystems Inc Verwendung hoch paralleler snp-genotypisierung zur fötalen diagnose
US8137912B2 (en) 2006-06-14 2012-03-20 The General Hospital Corporation Methods for the diagnosis of fetal abnormalities
EP2589668A1 (de) 2006-06-14 2013-05-08 Verinata Health, Inc Analyse seltener Zellen mittels Probentrennung und DNA-Etiketten
US20080050739A1 (en) 2006-06-14 2008-02-28 Roland Stoughton Diagnosis of fetal abnormalities using polymorphisms including short tandem repeats
US20110200597A1 (en) * 2008-08-05 2011-08-18 George Mason Intellectual Properties, Inc. Signal pathway alterations and drug target elevations in primary metachronous metastatic colorectal cancer compared to non-metastatic disease
CA3069082C (en) 2008-09-20 2022-03-22 The Board Of Trustees Of The Leland Stanford Junior University Noninvasive diagnosis of fetal aneuploidy by sequencing

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994007139A1 (en) * 1992-09-14 1994-03-31 Fodstad Oystein Improved method for detection of specific target cells in specialized or mixed cell population and solutions containing mixed cell populations
WO1997037226A1 (en) * 1996-03-29 1997-10-09 Mayo Foundation For Medical Education And Research Methods of recovering colorectal epithelial cells or fragments thereof from stool
DE19736691A1 (de) * 1997-08-22 1999-02-25 Michael Prof Dr Med Giesing Verfahren zur Charakterisierung und Identifizierung disseminierter und metastasierter Krebszellen
WO1999044064A1 (en) * 1998-02-27 1999-09-02 Cli Oncology, Inc. Method and compositions for differential detection of primary tumor cells and metastatic cells

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994007139A1 (en) * 1992-09-14 1994-03-31 Fodstad Oystein Improved method for detection of specific target cells in specialized or mixed cell population and solutions containing mixed cell populations
WO1997037226A1 (en) * 1996-03-29 1997-10-09 Mayo Foundation For Medical Education And Research Methods of recovering colorectal epithelial cells or fragments thereof from stool
DE19736691A1 (de) * 1997-08-22 1999-02-25 Michael Prof Dr Med Giesing Verfahren zur Charakterisierung und Identifizierung disseminierter und metastasierter Krebszellen
WO1999044064A1 (en) * 1998-02-27 1999-09-02 Cli Oncology, Inc. Method and compositions for differential detection of primary tumor cells and metastatic cells

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
BURCHILL S A ET AL: "DETECTION OF EPITHELIAL CANCER CELLS IN PERIPHERAL BLOOD BY REVERSETRANSCRIPTASE-POLYMERASE CHAIN REACTION", BRITISH JOURNAL OF CANCER, LONDON, GB, vol. 71, no. 2, 1995, pages 278 - 281, XP000562468, ISSN: 0007-0920 *
FUJIWARA Y ET AL: "ASSESSMENT OF STANNIOCALCIN-1 MRNA AS A MOLECULAR MARKER FOR MICROMETASTASES OF VARIOUS HUMAN CANCERS", INTERNATIONAL JOURNAL OF ONCOLOGY, EDITORIAL ACADEMY OF THE INTERNATIONAL JOURNAL OF ONCOLOGY,, GR, vol. 16, April 2000 (2000-04-01), pages 799 - 804, XP002938551, ISSN: 1019-6439 *
GHOSSEIN R A ET AL: "Molecular detection of micrometastases and circulating tumor cells in solid tumors", CLINICAL CANCER RESEARCH, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 5, no. 8, August 1999 (1999-08-01), pages 1950 - 1960, XP002225510, ISSN: 1078-0432 *
HARDINGHAM J E ET AL: "IMMUNOBEAD-PCR: A TECHNIQUE FOR THE DETECTION OF CIRCULATING TUMOR CELLS USING IMMUNOMAGNETIC BEADS AND THE POLYMERASE CHAIN REACTION", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 53, 1 August 1993 (1993-08-01), pages 3455 - 3458, XP000605489, ISSN: 0008-5472 *
ITO M ET AL: "EXPRESSION OF SEVERAL GROWTH FACTORS AND THEIR RECEPTOR GENES IN HUMAN COLON CARCINOMAS", VIRCHOWS ARCHIV B CELL PATHOLOGY INCLUDING MOLECULAR PATHOLOGY, vol. 59, no. 3, 1990, pages 173 - 178, XP009015191, ISSN: 0340-6075 *
NOTTERMAN DANIEL A ET AL: "Transcriptional gene expression profiles of colorectal adenoma, adenocarcinoma, and normal tissue examined by oligonucleotide arrays.", CANCER RESEARCH, vol. 61, no. 7, 1 April 2001 (2001-04-01), pages 3124 - 3130, XP002250499, ISSN: 0008-5472 *
REN-HEIDENREICH L ET AL: "SPECIFIC TARGETING OF EGP-2+ TUMOR CELLS BY PRIMARY LYMPHOCYTES MODIFIED WITH CHIMERIC T CELL RECEPTORS", HUMAN GENE THERAPY, XX, XX, vol. 11, no. 1, 1 January 2000 (2000-01-01), pages 9 - 19, XP000944357, ISSN: 1043-0342 *
SMITH B ET AL: "DETECTION OF MELANOMA CELLS IN PERIPHERAL BLOOD BY MEANS OF REVERSE TRANSCRIPTASE AND POLYMERASE CHAIN REACTION", LANCET THE, LANCET LIMITED. LONDON, GB, vol. 338, 16 November 1991 (1991-11-16), pages 1227 - 1229, XP002008751, ISSN: 0140-6736 *
ZHONG X Y ET AL: "EVALUATING GA733-2 MRNA AS A MARKER FOR THE DETECTION OF MICROMETASTATIC BREAST CANCER IN PERIPHERAL BLOOD AND BONE MARROW", ARCHIVES OF GYNECOLOGY AND OBSTETRICS, SPRINGER VERLAG, BERLIN, DE, vol. 263, no. 1/2, 1999, pages 2 - 6, XP000929386, ISSN: 0932-0067 *

Also Published As

Publication number Publication date
DE50209932D1 (de) 2007-05-24
WO2003023059A2 (de) 2003-03-20
ES2284927T3 (es) 2007-11-16
EP1409745B1 (de) 2007-04-11
EP1409745A2 (de) 2004-04-21

Similar Documents

Publication Publication Date Title
WO2001040269A3 (en) Compositions and methods for therapy and diagnosis of breast cancer
AU2001253079A1 (en) Methods, compositions and kits for the detection and monitoring of breast cancer
WO2001000828A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2000060076A3 (en) Compositions for the treatment and diagnosis of breast cancer and methods for their use
WO2001096388A8 (en) Compositions and methods for the therapy and diagnosis of colon cancer
WO2001072295A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
NZ330887A (en) Monoclonals and polyclonals antibodies for the diagnosis of breast cancer
WO2001079286A3 (en) Compositions and methods for the therapy and diagnosis of breast cancer
WO2004037999A3 (en) A34 and a33-like 3 dna, proteins, antibodies thereto and methods of treatment using same
WO2000060077A3 (en) Compounds for therapy and diagnosis of lung cancer and methods for their use
WO2002004514A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2002092001A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2003023059A3 (de) Verfahren und kit zur diagnostik oder behandlungskontrolle von darmkrebs
WO2000052165A3 (en) Compositions and methods for breast cancer therapy and diagnosis
WO2001073027A3 (en) Compositions and methods for therapy and diagnosis of colon cancer
WO2003037267A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2001018046A3 (en) Ovarian tumor sequences and methods of use therefor
WO2001077168A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2003023060A3 (de) Verfahren und kit zur diagnostik oder behandlungskontrolle von brustkrebs
WO2001090152A3 (en) Compositions and methods for the therapy and diagnosis of breast cancer
EP0839908A3 (de) ELF3, ein Mitglied der ETS-Familie
WO2001057207A3 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
WO2002000174A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2001070976A3 (en) Compositions and methods for the therapy and diagnosis of ovarian and endometrial cancer
WO2002062203A3 (en) Compositions and methods for the therapy and diagnosis of breast cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FR GB GR IE IT LU MC NL PT SE SK TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2002772273

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002772273

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2006246430

Country of ref document: US

Ref document number: 10488728

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 10488728

Country of ref document: US

WWG Wipo information: grant in national office

Ref document number: 2002772273

Country of ref document: EP